Access cutting-edge borderline-resectable pancreatic cancer treatment through this clinical trial at a research site in Indianapolis. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Indianapolis location
Preparing your pre-screening questions…
Access borderline-resectable pancreatic cancer specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related borderline-resectable pancreatic cancer treatment provided free
Check if you qualify for this borderline-resectable pancreatic cancer clinical trial in Indianapolis, IN
No-Cost Study Care
Local to Indianapolis
Convenient for IN residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The goal of this study is to test whether chemotherapy guided by a new imaging method named DCE-MRI can more effectively reduce a pancreatic tumor, enabling curable surgery, over the conventional method when a tumor is categorized as borderline resectable pancreatic cancer. UAB radiological research team has been studying a cutting-edge imaging technique named dynamic contrast-enhanced magnetic resonance imaging, or DCE-MRI, for over 10 years. This technique has been globally used to calculate the blood flow of various tissues, including tumors. Blood flow often serves as a critical indicator showing a disease status. For example, a pancreatic tumor typically has low blood flow, so it can be used as an indicator to identify the presence of a pancreatic tumor. In addition, an effective therapy can result in the increase of blood flow in a pancreatic tumor during the early period of treatment. Therefore, the investigators may be able to determine whether the undergoing therapy is effective or not by measuring the change of blood flow in the pancreatic tumor and deciding whether to continue the therapy or try a different one.
Sponsor: Ohio State University
Yes, this clinical trial (NCT06173310) has an active research site in Indianapolis, IN that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for borderline-resectable pancreatic cancer treatment options in Indianapolis, IN, this clinical trial (NCT06173310) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Indianapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced borderline-resectable pancreatic cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all borderline-resectable pancreatic cancer clinical trials near you to find additional studies recruiting in your area.
See all pancreatic cancer clinical trials recruiting in Indianapolis — not just this study.
Browse Pancreatic Cancer Trials in Indianapolis →